Background The ODYSSEY COMBO I study (http://clinicaltrials.gov/show/NCT01644175) evaluated efficacy and safety of alirocumab as add-on therapy to stable maximally tolerated daily statin with or without other lipid-lowering therapy in high cardiovascular risk patients with suboptimally controlled hypercholesterolemia.
Statin therapy is currently the most effective approved therapeutic intervention for lowering low-density lipoprotein cholesterol (LDL-C), with reductions of up to 55% depending on statin and dose. 1, 2 The magnitude of clinical benefit attributable to statin therapy is directly proportional to the level of pretreatment atherosclerotic cardiovascular disease (ASCVD) risk and magnitude of reduction in LDL-C. [1] [2] [3] Currently, available nonstatin lipid-lowering therapies (LLTs) have limited efficacy, with bile acid resins, nicotinic acid, and fibrates decreasing LDL-C by 10% to 20% on average and ezetimibe-lowering LDL-C by 15% to 20% on average. 4, 5 Therefore, considerable interest exists in the development of nonstatin therapies that more effectively reduce LDL-C and other atherogenic lipid parameters in high-risk patients on maximally tolerated doses of statin therapy and for those who are statin intolerant.
Recent interest has focused on proprotein convertase subtilisin/kexin type 9 (PCSK9) as a possible therapeutic target. Alirocumab, a fully human monoclonal antibody to PCSK9, has demonstrated significant reductions in LDL-C, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B, and lipoprotein (a) when administered in clinical trials to patients with hypercholesterolemia despite statin therapy. [6] [7] [8] [9] ODYSSEY COMBO I (NCT01644175) is a randomized, placebo-controlled, 52-week efficacy and safety study of alirocumab administered every 2 weeks (Q2W) as add-on therapy to stable, maximally tolerated daily statin therapy (with or without other LLT) in patients at high ASCVD risk. 10 This study, and others within the ODYSSEY program, uses a treat-to-target dosing strategy whereby the alirocumab dose may be increased depending on individual patient response.
Methods
This study was performed at 76 sites in the United States in accordance with the ethical principles of the Declaration of Helsinki and the International Conference on Harmonization/Good Clinical Practice. The protocol was reviewed and approved by the institutional review board of each participating center, and all participants provided written informed consent.
Full methods have been previously reported. 10 Briefly, male or female patients aged ≥18 years could participate if they had either (a) LDL-C ≥70 mg/dL and established CVD or (b) LDL-C ≥100 mg/dL with coronary heart disease (CHD) risk equivalents (eg, diabetes mellitus with other risk factors or chronic kidney disease). All patients were receiving a stable, maximally tolerated statin dose (defined as atorvastatin, 40-80 mg; rosuvastatin, 20-40 mg; or simvastatin, 80 mg daily; or lower doses provided the investigator had a documented reason for not using the higher dose, eg, intolerance and local practice) with or without other LLT (bile acid sequestrant, ezetimibe, niacin, or omega-3 ≥1000 mg/day with stable dose ≥4 weeks; or fenofibrate with stable dose ≥6 weeks before enrollment). Exclusion criteria and definitions of CVD and CHD risk equivalents are given in the online Appendix.
Eligible patients were randomized 2:1 to receive either alirocumab 75-mg Q2W, self-administered subcutaneously via 1 mL prefilled pen, or a matching placebo. Randomization was stratified by history of myocardial infarction or ischemic stroke and intensity of concomitant statin treatment (high intensity [atorvastatin, 40-80 mg daily; and rosuvastatin, 20-40 mg daily] or not high intensity). If LDL-C level was ≥70 mg/dL at week 8, alirocumab was increased in an automated and blinded fashion without site or patient awareness to 150 mg subcutaneously Q2W (also 1 mL) at the week 12 visit.
On-site patient assessments were scheduled at randomization and subsequently at weeks 4, 8, 12, 16, 24, 36, and 52 . Injections were performed at home by the patient or a designated caregiver. Training for the person performing the injection was provided during screening. After completion of double-blind treatment, patients were followed up for an additional 8 weeks off study medication.
End points and assessments
The primary efficacy end point was the percent change in LDL-C from baseline to week 24, analyzed using an intention-to-treat (ITT) approach. Key secondary efficacy end points included percent change in LDL-C from baseline to week 24 (on-treatment analysis), percent change in LDL-C at other defined time points, percent changes in other lipid parameters, and proportion of patients reaching LDL-C b70 mg/dL. 10 All lipid analyses were performed by a central laboratory (Medpace Reference Laboratories, Cincinnati, OH), and LDL-C was calculated by the Friedewald formula.
11 Lowdensity lipoprotein cholesterol was also measured via β quantification at randomization (week 0) and week 24 (and in cases where triglycerides exceeded 400 mg/dL [4.52 mmol/L]). All other lipid parameters were measured directly. Anti-alirocumab antibodies were assessed in all patients regardless of treatment allocation at baseline (week 0) as well as weeks 12, 24, 52, and 60 (follow-up) .
Safety was assessed by adverse event (AE) reporting, including adjudicated CV events, laboratory analyses (including LDL-C b25 mg/dL on 2 consecutive measurements ≥21 days apart), and vital signs measurement. The safety population included all randomized patients who received ≥1 dose or an incomplete injection. The treatment-emergent AE (TEAE) period was defined as the time from first to last double-blind dose of study medication plus 70 days (10 weeks).
Statistical methodology
Statistical methods were described previously. 10 It was estimated that 45 randomized patients (30 alirocumab; 15 placebo) would provide 95% power to detect a mean percent change in LDL-C of ≥30% from baseline to 24 weeks with a 0.05 two-sided significance level, assuming an SD of 25%. To accommodate a maximum estimated subject drop-out rate of 30% (based on previous trials) at 52 weeks and to provide greater safety data to the ODYSSEY Phase 3 program, the sample size was increased to 306 patients.
The primary end point was assessed in the ITT population, which included all randomized patients regardless of treatment adherence with ≥1 available LDL-C value both at baseline and at one of the planned time points between weeks 4 and 24. A mixed effect model with repeated measures was used to account for missing data. All available postbaseline data from week 4 to week 52 were used regardless of status on or off treatment. The model included fixed categorical effects of treatment group, randomization strata, time point, treatment-by-time point interaction, and strata-by-time point interaction as well as the continuous fixed covariates of baseline LDL-C value and baseline value-bytime point interaction. This model provided baseline adjusted least squares means estimates at week 24 for both treatment groups with their corresponding 95% CIs.
The difference between these estimates will be provided with their corresponding 95% CI and P values.
A sensitivity analysis based on a pattern mixture model was conducted to evaluate the impact of missing data on the primary end point. In this approach, missing calculated LDL-C values during the on-treatment period were multiply imputed using a model assuming "missing at random"; missing calculated LDL-C values during the posttreatment period were multiply imputed using random draws from a normal distribution where the mean was equal to subject's own baseline value.
Secondary end points were analyzed in a predefined order using a hierarchical testing procedure to control type I error. These end points were analyzed with the same methodology as for the primary end point, except lipoprotein (a) and triglycerides, which were analyzed using a multiple imputation approach for handling of missing values followed by robust regression. The proportion of patients with LDL-C b70 mg/dL was analyzed using a multiple imputation approach for handling of missing values followed by logistic regression.
A prespecified on-treatment analysis was also conducted for the percent change in LDL-C from baseline to week 24 and key secondary end points, using all available on-treatment measurements at planned time points from weeks 4 to 52.
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Results
Of 640 patients screened for eligibility, 316 were subsequently randomized to alirocumab (209) or placebo (107) (Figure 1) . The ITT population included 311 (98.4%) patients (5 patients had missing LDL-C levels and were excluded from the ITT analysis); 309 patients comprised the on-treatment population, and 314 patients comprised the safety population. Baseline characteristics of randomized patients (Table I) were similar with no statistically significant differences between the treatment groups. Over the 52-week double-blind period, adherence to study medication (receipt of ≥80% scheduled injections) was similar between treatment groups (98% alirocumab; 99% placebo). Based on week 8 LDL-C levels ≥70 mg/dL, 32 (16.8%) of 191 patients had their alirocumab dose increased to 150 mg subcutaneously Q2W at week 12 (among patients with ≥1 injection after week 12).
Primary and secondary efficacy analyses
Estimated mean (95% CI) percent change from baseline to week 24 in LDL-C was −48.2% (−52.0% to −44.4%) for alirocumab and −2.3% (−7.6% to 3.1%) for placebo in the ITT analysis and −50.7% (−54.4% to −47.0%) and −0.8% (−5.9% to 4.3%), respectively, for the on-treatment analysis (both P b .0001 for alirocumab vs placebo; Table II, Figure 2 , and online Supplementary Table I) . Measured LDL-C results (β quantification) were Abbreviations: BMI, Body mass index; Apo, apolipoprotein; Lp(a), lipoprotein (a); TGs, triglycerides. ⁎ Coronary heart disease risk equivalents were defined as ischemic stroke, peripheral artery disease, moderate chronic kidney disease, or diabetes (only if ≥2 risk factors present). † High-dose statin: atorvastatin, 40 to 80 mg or rosuvastatin, 20 to 40 mg or simvastatin, 80 mg daily. ‡ Low-density lipoprotein cholesterol was calculated using the Friedewald formula and also measured by β quantification. The collection of measured LDL-C was not planned in the initial protocol and was added in an amendment. Therefore, measured LDL-C values are available for fewer patients compared with calculated LDL-C values. At baseline, LDL-C was measured for 138 alirocumab and 70 placebo patients. § Median (Q1:Q3).
consistent with those for calculated LDL-C (Table II) .
Results of a sensitivity analysis of the primary end point were consistent with the ITT analysis (online Supplementary Table I) . Achieved LDL-C reduction over time ( Figure 3 ) demonstrates early (4 weeks) and sustained (52 weeks) reduction in LDL-C compared with placebo. At week 12, before possible alirocumab dose increase (all alirocumab patients were receiving 75-mg Q2W), LDL-C reductions were 46.3% from baseline, comparable with those at week 24 (Table II) . The main baseline factor predictive of a dose increase at week 12 was baseline LDL-C level; distributions of baseline and week 24 LDL-C levels are shown in online Supplementary Figure 1 . Among the 32 patients (16.8%) with alirocumab dose increase at week 12 (based on LDL-C at week 8 ≥70 mg/ dL), achieved LDL-C was comparable at weeks 24, 36, and 52 with that observed among patients in whom no dose increment was performed (week 8 LDL-C b70 mg/dL) ( Figure 4 ). In patients with dose increase, LDL-C was reduced by an additional mean 22.8% (SD 27.1) at week 24 compared with week 12.
The relative proportions of patients achieving LDL-C b70 mg/dL (b1.81 mmol/L) at week 24 in the ITT (75.0%) and on-treatment (77.5%) analyses were significantly greater with alirocumab than placebo (9.0% and 8.0%, respectively; P b .0001) ( Figure 5 ).
Significant reductions from baseline to week 24 after therapy with alirocumab (P b .0001 vs placebo) were observed in non-HDL-C (−39.1% [−42.6% Figure 2 , and online Supplementary Tables II-VIII); no significant change was observed in triglyceride levels, whereas a significant and directionally divergent increase in HDL-C was observed after alirocumab of 3.5% (1.4%-5.6%) (vs −3.8% [−6.8% to −0.8%] placebo; P b .0001) (Table II) . Additional analysis of patients in the highest quartile of baseline lipoprotein (a) (N79.5 mg/dL; 73 patients) revealed a mean percent change in lipoprotein (a) from baseline to week 24 (alirocumab vs placebo) similar to that observed in the overall study population (−16.5% vs −14.6%, respectively). Patients in the highest quartile of baseline triglyceride (N186 mg/dL; 75 patients) had adjusted mean percent changes in triglyceride level from baseline to week 24 of −18.8% Primary analyses were conducted using an ITT approach including all lipid data regardless of whether the patient was receiving study treatment. ⁎ Sensitivity analysis; P value for descriptive purpose only. † Combined estimate for adjusted mean (95% CI) shown for lipoprotein (a) and triglycerides.
Figure 3
Achieved calculated LDL-C levels over time with alirocumab and placebo on background maximally tolerated statin with or without other LLT (ITT analysis). Baselines are described using mean; all other time points are estimated mean (95% CI). Values above and below data points indicate estimated mean percent change from baseline and estimated mean achieved LDL-C levels.
Figure 2
End point analysis: percent reduction in LDL-C and other lipid parameters from baseline to week 24.
and −23.6% after alirocumab or placebo, respectively. There was no difference in response between placebo and alirocumab-treated patients (combined estimate for adjusted mean percent difference vs placebo of 4.8; P = .6069).
Subgroup analyses
Alirocumab produced 40% to 55% mean reduction in LDL-C across prespecified subgroups including age, gender, race, ethnicity, intensity of background statin therapy, other LLT therapy (in addition to statin), and history of myocardial infarction or ischemic stroke ( Figure 6 ). Greater variation in LDL-C reductions was observed with placebo for some subgroups, particularly those with small sample sizes (such as ethnicity [Hispanic/Latino]), producing large CIs for the difference in treatment effect for alirocumab versus placebo. Although treatment effect was generally consistent across subgroups, some heterogeneity in treatment effect (P value for interaction b .05) was observed for patients with other LLT therapy (in addition to statin) and those with a history of myocardial infarction or ischemic stroke.
Safety measures
The incidences of TEAEs and serious TEAEs were similar between treatment groups (Table III and online  Supplementary Table IX) . Treatment-emergent AEs leading to death or study medication discontinuation were uncommon in both groups (Table III) . Local injection site reactions, reported by 5.3% alirocumab-treated patients (vs 2.8% placebo), were mild in severity and did not prompt study medication discontinuation. Adverse events related to potential general allergic reactions occurred in 8.7% alirocumab versus 6.5% placebo patients. There were few neurologic or neurocognitive events. Laboratory assessments were similar between groups and between alirocumab patients maintained on the 75-mg dose or those increased to 150-mg Q2W. Low-density lipoprotein cholesterol percent reduction in patients with and without alirocumab dose increase.
Figure 5
Proportion of patients reaching LDL-C b70 mg/dL (1.81 mmol/L) at week 24. Multiple imputation method is used to address missing values in the ITT and modified ITT populations. Combined estimate for proportion of patients is obtained by averaging out all the imputed proportions of patients reaching the level of interest. The P value is statistically significant according to the fixed hierarchical approach used to ensure a strong control of the overall type I error rate at the 0.05 level.
Low-density lipoprotein cholesterol levels b25 mg/dL (on 2 consecutive measurements ≥21 days apart) were observed in 39 alirocumab-treated patients, of whom 9 had LDL-C b15 mg/dL. The overall AE profile appeared similar to those patients without such low LDL-C levels (online Supplementary Table X) . No placebotreated patients reached LDL-C levels of b25 mg/ dL on 2 consecutive measurements.
Anti-alirocumab antibodies
A total of 13 alirocumab-treated patients (of 197 evaluable patients; 6.6%) had a positive response for the anti-alirocumab antibody assay. Five patients randomized to alirocumab (3/197; 1.5%) or placebo (2/99; 2.0%) had preexisting immunoreactivity. Treatment-emergent and low-titer antibody response was observed in 13 (6.6%) of 197 alirocumab-treated patients, in 7 of whom the antibodies were transient and resolved despite continued alirocumab treatment. Dose increase at week 12 did not appear to contribute to the development of antibodies. Of 8 patients with a positive response for the antialirocumab antibody assay at week 24, 2 had a dose increase in alirocumab to 150-mg Q2W at week 12; in both of these patients, antibodies were transient and resolved by week 52. Of the 13 alirocumab-treated patients positive in the anti-alirocumab antibody assay, 4 were positive for alirocumab-neutralizing antibodies; each of these resolved (became negative) within 24 weeks. The median time to detection of antibodies to alirocumab was 12 weeks, and no specific clinical events were observed in antibodypositive patients. The presence of anti-alirocumab antibodies had no observed effect on LDL-C-lowering efficacy (online Supplementary Figure 2) or safety.
Discussion
Self-administered alirocumab versus placebo added to maximally tolerated statin therapy with or without other LLT was associated with (a) a 48% reduction from baseline (pretreatment) to 24 weeks in LDL-C, corresponding to achieved estimated mean LDL-C levels of 51 mg/dL (vs 98 mg/dL with placebo); (b) significant reductions in non-HDL-C, total cholesterol, apolipoprotein B, and lipoprotein (a); and (c) a greater portion of patients who achieved LDL-C b70 mg/dL (75% vs 9%). These efficacy data complement clinical trial results using alirocumab as monotherapy 8 and are consistent with previous phase 2 trial results. 6, 7, 9 COMBO I used a treat-to-target level dosing strategy based on individual patient responses to alirocumab treatment. Most (83% of those with an injection after week 12) high CV risk patients on background statin therapy achieved an LDL-C b70 mg/dL on the 75-mg Q2W alirocumab dose regimen at week 8 and did not need dose increase to 150-mg Q2W. These patients demonstrated consistent efficacy over time. Low-density lipoprotein cholesterol reduction for weeks 24 to 52 was comparable among those patients in whom alirocumab dose was increased to 150 mg at week 12 (LDL-C ≥70 mg/dL at week 8) and those who remained on alirocumab 75 mg throughout the duration of the study. In this study, increase in alirocumab dose produced an additional 22.8% reduction in LDL-C, providing rationale for initiation of alirocumab therapy using the 75-mg dose with the potential to increase to 150 mg if further LDL-C reduction is required.
When administered in conjunction with maximally tolerated statin with or without additional LLT, alirocumab treatment appeared to be generally well tolerated over 52 weeks of therapy, with incidences of TEAEs and serious AEs largely comparable with those observed on placebo. Injection site reactions occurred more frequently in alirocumab-treated patients versus placebo; however, consistent with previous reports, 6-9 they were mostly graded mild in severity. Development of anti-alirocumab antibodies was observed in 6.6% of evaluable alirocumabtreated patients; however, these were transient (despite continued treatment) in almost two-thirds of cases, and there was no association between development of antibodies and clinical sequelae or LDL-C lowering. Overall safety findings were similar to other alirocumab studies reported thus far [6] [7] [8] [9] and for other PCSK9 inhibitors. 12 Although sufficiently powered to detect the primary end point of LDL-C reduction from baseline to week 24, this study remains relatively small with respect to subgroup analyses. Analysis using pooled data from the multinational ODYSSEY phase 3 program will provide more comprehensive assessment in terms of consistency of alirocumab treatment effect across subgroups (including in patients with LDL-C b25 mg/dL) and patient populations. COMBO I provided further demonstration of the LDL-C-lowering efficacy and safety of alirocumab in a high CV risk population; however, clinical outcomes data .9) 3 (2.8) CHD death (including undetermined cause) 1(0.5) 1 (0.9) Nonfatal myocardial infarction 1(0.5) 1 (0.9) Fatal and nonfatal ischemic stroke (including stroke not otherwise specified) 2 (1.0) 0 Unstable angina requiring hospitalization 0 0 Congestive heart failure requiring hospitalization 0 1 (0.9) Ischemia-driven coronary revascularization procedure 3 (1.4) 1 (0.9)
Abbreviations: SAEs, Serious AEs. ⁎ Neurocognitive events were selected using a company Medical Dictionary for Regulatory Activities query based on the following 5 high-level group terms: deliria (including confusion), cognitive and attention disorders and disturbances, dementia and amnestic conditions, disturbances in thinking and perception, and mental impairment disorders. † One patient in the placebo group and 1 patient in the alirocumab group each experienced 2 events that were positively adjudicated: nonfatal myocardial infarction and ischemiadriven coronary revascularization procedure.
(currently being collected in the OUTCOMES trial NCT01663402) are required to corroborate any potential benefit with respect to CV events. In patients at high ASCVD risk with hypercholesterolemia despite treatment with maximally tolerated statin (with or without other LLT), alirocumab reduced LDL-C through 52 weeks of treatment and was well tolerated. Alirocumab 75-mg Q2W was sufficient for a majority of patients to achieve LDL-C b70 mg/dL without the need for subsequent dose increase to 150 mg. These findings provide support for initiating alirocumab therapy at 75-mg Q2W in patients on maximized standard of care who have suboptimally controlled hypercholesterolemia, with dose increase to 150-mg Q2W in those patients not achieving LDL-C lower than 70 mg/dL.
The definitions of CHD included acute myocardial infarction, silent myocardial infarction, unstable angina, coronary revascularization, or clinically significant CHD diagnosed by invasive or noninvasive testing. Coronary heart disease risk equivalents included peripheral arterial disease, ischemic stroke, chronic kidney disease (estimated glomerular filtration rate ≥30 to b60 mL/min per 1.73 m 2 for ≥3 months), or diabetes mellitus in combination with ≥2 additional risk factors (hypertension, ankle-brachial index ≤0.90, microalbuminuria or macroalbuminuria, dipstick urinalysis with N2+ protein, retinopathy, or family history of premature CHD [b55 years in father/brother or b65 years in mother/sister]). Specific protocol-defined exclusion criteria included known hypersensitivity to monoclonal antibody therapeutics, women of childbearing potential with no effective contraceptive method, uncontrolled diabetes with hemoglobin A1C N8.5% or diagnosed within 3 months, clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins, blood pressure N160/100 mm Hg, major CV event within 3 months, New York Heart Association class III or IV, heart failure within 12 months, fasting serum triglycerides N400 mg/dL (4.52 mmol/L), thyroid-stimulating hormone either below or above the upper limit of normal, alanine aminotransferase, aspartate aminotransferase, or creatine phosphokinase N3× upper limit of normal.
Additional statistical methodology
A mixed effect model with repeated measures was used to account for missing data and included fixed categorical effects of treatment group, randomized strata, time point, treatment-by-time point interaction, and strata-by-time point interaction as well as the continuous fixed covariates of baseline LDL-C value and baseline value-bytime point interaction. A sensitivity analysis based on a pattern mixture model was conducted to evaluate the impact of missing data on the primary end point; in this approach, missing calculated LDL-C values during the on-treatment period were multiply imputed using a model assuming "missing at random"; missing calculated LDL-C values during the posttreatment period were multiply imputed using random draws from a normal distribution where the mean was equal to subject's own baseline value.
Secondary end points were analyzed in a predefined order using a hierarchical testing procedure to control type I error. Secondary lipid end points were analyzed as for the primary end point, except lipoprotein (a) and triglycerides, which were analyzed using a multiple imputation approach for handling of missing values followed by robust regression.
The proportion of patients with LDL-C b70 mg/dL was analyzed by logistic regression.
A prespecified on-treatment analysis was also conducted for the percent change in LDL-C from baseline to week 24 and key secondary end points, using all available on-treatment measurements at planned time points from weeks 4 to 52. Values are mean (SD) unless stated.
Supplementary
Only patients who were receiving study treatment were included in the on-treatment analysis (modified ITT). The sensitivity analysis has been conducted to further evaluate the impact of missing data on the primary end point: in this approach, missing calculated LDL-C values during the "on-treatment" period were multiply imputed using a model assuming missing at random, and missing calculated LDL-C values during the posttreatment period were multiply imputed using random draws from a normal distribution, with mean equal to subject's own baseline value. 
